

Publications NGMB 2011

Ph.D. theses:

1. Agool A. PET and SPECT imaging of bone marrow disorders. Ph.D. thesis, University of Groningen, March 2, 2011. [Promotores: Vellenga E, **Dierckx RA**, co-promotor: **Slart RH**]
2. Dijkers ECF. Development of new radiopharmaceuticals for molecular imaging in oncology. Ph.D. thesis, University of Groningen, November 28, 2011 [Promotores: De Vries EGE, **Dierckx RA**, Kosterink JGW, co-promotor: **Lub-de Hooge MN**]
3. Heijink DM. Preclinical leads for chemoprevention of colorectal cancer: novel strategies to regulate apoptosis and proliferation. Ph.D.thesis, University of Groningen, April 27, 2011. [in this thesis, Apc mutant mice with intestinal adenomas were scanned with 18F-FDG and microPET]
4. Klerk OL de. The Guarded Brain. The Role of P-glycoprotein at the blood-brain barrier in major psychiatric disorders and antidepressant treatment. Ph.D. thesis, University of Groningen, December 21, 2011. [Promotores: Den Boer JA, **Dierckx RA**, co-promotores: Bosker FJ, **Willemsen ATM**]
5. Malviya G. Radiolabelled monoclonal antibodies for molecular imaging of chronic inflammatory diseases. Ph.D. thesis, University of Groningen, February 23, 2011. [Promotores: **Signore A**, **Dierckx RA**, co-promotor: **De Vries EFJ**]
6. Oude Munnink, T. PET imaging with zirconium-89 labeled antibodies to guide cancer therapy. Ph.D. thesis, University of Groningen, October 5, 2011 [Promotores De Vries EGE, **Dierckx RA**, co-promotores **Lub-de Hooge MN**, **Brouwers AH**, Schröder CP]

Full papers in international journals:

1. **Abdoli M, de Jong JR, Pruijm J, Dierckx RA and Zaidi H.** Reduction of artefacts caused by hip implants in CT-based attenuation-corrected PET images using 2-D interpolation of a virtual sinogram on an irregular grid. *Eur J Nucl Med Mol Imaging* 38: 2257-2268, 2011.
2. **Agool A, Glaudemans AW, Boersma HH, Dierckx RA, Vellenga E and Slart RH.** Radionuclide imaging of bone marrow disorders. *Eur J Nucl Med Mol Imaging* 38: 166-178, 2011.
3. **Agool A, Slart RH, Kluin PM, de Wolf JT, Dierckx RA and Vellenga E.** F-18 FLT PET: A Noninvasive Diagnostic Tool for Visualization of the Bone Marrow Compartment in Patients With Aplastic Anemia: A Pilot Study. *Clin Nucl Med* 36: 286-289, 2011.

4. **Agool A, Slart RH, Thorp KK, Glaudemans AW, Cobben DC, Been LB, Burlage FR, Elsinga PH, Dierckx RA, Vellenga E and Holter JL.** Effect of radiotherapy and chemotherapy on bone marrow activity: a ¹⁸F-FLT-PET study. *Nucl Med Commun* 32: 17-22, 2011.
5. **Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, Yan Y, Chen X, de Jong IJ and Elsinga PH.** (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) as a Targeted Imaging Agent with MicroSPECT in a PC-3 Prostate Cancer Xenograft Model. *Mol Pharm* 8: 1165-1173, 2011.
6. **Ay MR, Mehranian A, Abdoli M, Ghafarian P and Zaidi H.** Qualitative and Quantitative Assessment of Metal Artifacts Arising from Implantable Cardiac Pacing Devices in Oncological PET/CT Studies: A Phantom Study. *Mol Imaging Biol* 13: 1077-1087, 2011.
7. **Boersma HH, de Haas HJ, Reutelingsperger CP and Slart RH.** P-selectin imaging in cardiovascular disease: what you see is what you get? *J Nucl Med* 52: 1337-1338, 2011.
8. **Bremmer JP, van Berckel BN, Persoon S, Kappelle LJ, Lammertsma AA, Kloet R, Luurtsema G, Rijbroek A, Klijn CJ and Boellaard R.** Day-to-day test-retest variability of CBF, CMRO₂, and OEF measurements using dynamic ¹⁵O PET studies. *Mol Imaging Biol* 13: 759-768, 2011.
9. **Bruggink JL, Slart RH, Pol JA, Reijnen MM, Zeebregts CJ.** Current role of imaging in diagnosing aortic graft infections. *Semin Vasc Surg* 24: 182-190, 2011
10. **Campbell-Verduyn LS, Mirfeizi L, Schoonen AK, Dierckx RA, Elsinga PH and Feringa BL.** Strain-Promoted Copper-Free "Click" Chemistry for (¹⁸F) Radiolabeling of Bombesin. *Angew Chem Int Ed Engl* 50: 11117-11120, 2011.
11. **Chianelli M, Signore A, Mansi L and Salvatori M.** Time for radiobiology in the nuclear medicine community. *Eur J Nucl Med Mol Imaging* 38: 1267-1269, 2011.
12. **Crane LM, Themelis G, Arts HJ, Buddingh KT, Brouwers AH, Ntziachristos V, van Dam GM and van der Zee AG.** Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. *Gynecol Oncol* 120: 291-295, 2011.
13. **de Klerk OL, Bosker FJ, Luurtsema G, Nolte IM, Dierckx R, den Boer JA and Potschka H.** The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain? *Cent Nerv Syst Agents Med Chem* 11: 197-209, 2011.
14. **de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruijm J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ and Hoekstra OS.** Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. *J Nucl Med* 52: 48-55, 2011.

15. **de Vries M, Speijers MJ, Bastiaannet E, Plukker JT, Brouwers AH, van Ginkel RJ, Suurmeijer AJ and Hoekstra HJ.** Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. *Eur J Surg Oncol* 37: 681-687, 2011.
16. **Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJ and Boerman OC.** PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides. *Eur J Nucl Med Mol Imaging* 38: 128-137, 2011.
17. **Dingemans AM, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HT, van Tinteren H, Hoekstra OS, Pruijm J, Brans B, Thunnissen FB, Smit EF and Groen HJ.** First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. *Ann Oncol* 22: 559-566, 2011.
18. **Eshuis SA, Dierckx RA, van Snick PJ, Slart RH and Glaudemans AW.** Manifestation of lymphoma expansion following lymphatic drainage on (18)F-FDG PET/CT. *Eur J Nucl Med Mol Imaging* 38: 2100-2101, 2011.
19. **Familiari D, Glaudemans AW, Vitale V, Prospero D, Bagni O, Lenza A, Cavallini M, Scopinaro F and Signore A.** Can sequential 18F-FDG PET/CT replace WBC imaging in the diabetic foot? *J Nucl Med* 52: 1012-1019, 2011.
20. **Fanti S, Krause B, Weber W, Castellucci P, Grosu AL, de J, I, Messa C, Picchio M, Pruijm J, Langsteger W and Chiti A.** Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. *Eur Urol* 2011;59:572-83. *Eur Urol* 60: e37-e38, 2011.
21. **Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, Walenkamp AM, Links TP, Brouwers AH and de Vries EG.** Total (18)F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. *Eur J Nucl Med Mol Imaging* 38: 1854-1861, 2011.
22. **Fiebrich HB, Siemerink EJ, Brouwers AH, Links TP, Remkes WS, Hospers GA and de Vries EG.** Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. *Oncologist* 16: 783-787, 2011.
23. **Fiebrich HB, de J, Jr., Kema IP, Koopmans KP, Sluiter W, Dierckx RA, Walenkamp AM, Links TP, Brouwers AH and de Vries EG.** Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. *Eur J Nucl Med Mol Imaging* 38: 1854-1861, 2011.

24. **Glaudemans AW, Slart RH and Pruim J.** Panniculitis-like T-cell lymphoma detected by positron emission tomography/computed tomography scanning in a patient with haemophagocytic syndrome. *Eur J Haematol* 87: 379, 2011.
25. **Heijink DM, Kleibeuker JH, Nagengast WB, Oosterhuis D, Brouwers AH, Koornstra JJ, de Jong S and de Vries EG .** Total abdominal 18F-FDG uptake reflects intestinal adenoma burden in Apc mutant mice. *J Nucl Med* 52: 431-436, 2011.
26. **Hermus L, Schuitemaker JH, Tio RA, Breek JC, Slart RH, de Boef E and Zeebregts CJ.** Novel serum biomarkers in carotid artery stenosis: Useful to identify the vulnerable plaque? *Clin Biochem* 44: 1292-1298, 2011.
27. **Jager-Wittenaar H, Dijkstra PU, Vissink A, Langendijk JA, van der Laan BF, Pruim J and Roodenburg JL.** Changes in nutritional status and dietary intake during and after head and neck cancer treatment. *Head Neck* 33: 863-870, 2011.
28. **Jager PL, Jonkman S, Koolhaas W, Stiekema A, Wolffenbuttel BH and Slart RH.** Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations. *Osteoporos Int* 22: 1059-1068, 2011.
29. **Kruijff S, Bastiaannet E, Speijers MJ, Kobold AC, Brouwers AH and Hoekstra HJ.** The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. *Eur J Surg Oncol* 37: 225-232, 2011.
30. **Kuchenbecker WK, Groen H, van Asselt SJ, Bolster JH, Zwerver J, Slart RH, Van der Jagt EJ, Muller Kobold AC, Wolffenbuttel BH, Land JA and Hoek A.** In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. *Hum Reprod* 26: 2505-2512, 2011.
31. **Lubberink M, Wong YY, Raijmakers PG, Schuit RC, Luurtsema G, Boellaard R, Knaapen P, Vonk-Noordegraaf A and Lammertsma AA.** Myocardial oxygen extraction fraction measured using bolus inhalation of 15O-oxygen gas and dynamic PET. *J Nucl Med* 52: 60-66, 2011.
32. **Malviya G, de Vries EF, Dierckx RA and Signore A.** Synthesis and Evaluation of (99m)Tc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression. *Mol Imaging Biol* 13: 930-939, 2011.
33. **Masteling MG, Zeebregts CJ, Tio RA, Breek JC, Tietge UJ, de Boer JF, Glaudemans AW, Dierckx RA, Boersma HH and Slart RH.** High-resolution imaging of human atherosclerotic carotid plaques with micro(18)F-FDG PET scanning exploring plaque vulnerability. *J Nucl Cardiol* 18: 1066-1075, 2011.

34. **Mees G, Vangestel C, Dierckx RA, Loomans S, Van Damme N, Peremans K, De Rooster H, Van Goethem B, Pauwels P, Ducatelle R, Van de Wiele C.** Metabolic correlates of tumour hypoxia in malignant canine mammary carcinoma. *Res Vet Sci* 91: e125-e128, 2011
35. **Muijs CT, Beukema JC, Widder J, van den Bergh AC, Havenga K, Pruijm J and Langendijk JA.** 18F-FLT-PET for detection of rectal cancer. *Radiother Oncol* 98: 357-359, 2011.
36. **Nagengast WB, Hooge MN, van Straten EM, Kruijff S, Brouwers AH, den Dunnen WF, de Jong JR, Hollema H, Dierckx RA, Mulder NH, de Vries EG, Hoekstra HJ and Hospers GA.** VEGF-SPECT with (111)In-bevacizumab in stage III/IV melanoma patients. *Eur J Cancer* 47: 1595-1602, 2011.
37. **Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, de Jong JR, Price PM, Hollema H, Hospers GA, Elsinga PH, Hesselink JW, Gietema JA and de Vries EG.** VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. *Cancer Res* 71: 143-153, 2011.
38. **Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, Schroder CP, Hesselink JW, Vedelaar SR, Walenkamp AM, Reiss M, Gregory RC, Lub-de Hooge MN and de Vries EG.** PET with the 89Zr-Labeled Transforming Growth Factor-beta Antibody Fresolimumab in Tumor Models. *J Nucl Med* 52: 2001-2008, 2011.
39. **Paul S, Elsinga PH, Ishiwata K, Dierckx RA and van Waarde A.** Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging. *Curr Med Chem* 18:4820-4835,2011.
40. **Paul S, Khanapur S, Rybczynska AA, Kwizera C, Sijbesma JW, Ishiwata K, Willemsen AT, Elsinga PH, Dierckx RA and van Waarde A.** Small-animal PET study of adenosine A(1) receptors in rat brain: blocking receptors and raising extracellular adenosine. *J Nucl Med* 52: 1293-1300, 2011.
41. **Rachmawati H, Beljaars L, Reker-Smit C, Bakker HI, Loenen-Weemaes AM, Lub-de Hooge MN and Poelstra K.** Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in rats. *PDA J Pharm Sci Technol* 65: 116-130, 2011.
42. **Richter WS, Ivancevic V, Meller J, Lang O, Le GD, Szilvazi I, Amthauer H, Chossat F, Dahmane A, Schwenke C and Signore A.** 99mTc-besilesomab (Scintimun) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells. *Eur J Nucl Med Mol Imaging* 38: 899-910, 2011.

43. **Said SA, Nijhuis RL, Op den Akker JW, Kimman GP, Van Houwelingen KG, Gerrits D, Huisman AB, Slart RH, Nicastia DM, Koomen EM, Tans AC, Al-Windy NY, Sonker U, Slagboom T and Pronk AC.** Diagnostic and therapeutic approach of congenital solitary coronary artery fistulas in adults: Dutch case series and review of literature. *Neth Heart J* 19: 183-191, 2011.
44. **Scholtens AM, Tio RA, Willemsen A, Dierckx RA, Boersma HH, Zeebregts CJ, Glaudemans AW and Slart RH.** Myocardial perfusion reserve compared with peripheral perfusion reserve: A [¹³N]ammonia PET study. *J Nucl Cardiol* 18: 238-246, 2011.
45. **Signore A and Glaudemans AW .** The molecular imaging approach to image infections and inflammation by nuclear medicine techniques. *Ann Nucl Med* 25: 681-700, 2011.
46. **Slart RH.** Myocardial perfusion PET: A split function? *J Nucl Cardiol* 18: 544-546, 2011.
47. **Slart RH, Zeebregts CJ, Hillege HL, de Sutter J, Dierckx RA, van Veldhuisen DJ, Zijlstra F and Tio RA.** Myocardial perfusion reserve after a PET-driven revascularization procedure: a strong prognostic factor. *J Nucl Med* 52: 873-879, 2011.
48. **Syvänen S, Luurtsema G, Molthoff CF, Windhorst AD, Huisman MC, Lammertsma AA, Voskuyl RA and de Lange EC.** (R)-[¹¹C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus. *BMC Med Imaging* 11: 1, 2011.
49. **Terwisscha van Scheltinga AG, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JG, Lub-de Hooge MN and de Vries EG.** Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. *J Nucl Med* 52: 1778-1785, 2011.
50. **van den Bergh AC, Pruim J, Links TP, van der Vliet AM, Sluiter W, Wolffenbuttel BH, Langendijk JA, Hoving EW and Dullaart RP.** Tyrosine positron emission tomography and protein synthesis rate in pituitary adenoma: different effects of surgery and radiation therapy. *Radiother Oncol* 98: 213-216, 2011.
51. **van Dijk D, Plukker JT, van der Horst-Schrivers AN, Jansen L, Brouwers AH, Muller-Kobold A, Sluiter WJ and Links TP.** The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial (1)(3)(1)I therapy. *Clin Endocrinol (Oxf)* 74: 104-110, 2011.

52. **van Heijl M, Omloo JM, Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW and van Lanschot JJ.** Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. *Ann Surg* 253: 56-63, 2011.
53. **van Waarde A, Ramakrishnan NK, Rybczynska AA, Elsinga PH, Ishiwata K, Nijholt IM, Luiten PG and Dierckx RA.** The cholinergic system, sigma-1 receptors and cognition. *Behav Brain Res* 221: 543-554, 2011.
54. **Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, Reutelingsperger C, Van Damme N, De Spiegeleer B and Van de Wiele C.** In Vivo Imaging of Apoptosis in Oncology: An Update. *Mol Imaging* 10: 340-358, 2011.
55. **Visser AK, van Waarde A, Willemsen AT, Bosker FJ, Luiten PG, den Boer JA, Kema IP and Dierckx RA.** Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications. *Eur J Nucl Med Mol Imaging* 38: 576-591, 2011.
56. **Wang H, Yolken RH, Hoekstra PJ, Burger H and Klein HC.** Antibodies to infectious agents and the positive symptom dimension of subclinical psychosis: The TRAILS study. *Schizophr Res* 129: 47-51, 2011.
57. **Welling MM, Duijvestein M, Signore A and van der Weerd L.** In vivo biodistribution of stem cells using molecular nuclear medicine imaging. *J Cell Physiol* 226: 1444-1452, 2011.
58. **Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA and Widder J.** 18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. *Eur J Nucl Med Mol Imaging* 38: 1059-1063, 2011.
59. **Wierds R, de Jong, JR., Lazarenko SV, Paans AM, Dierckx RA and Willemsen AM.** Characteristics of a new system for monitoring the leakage factor during regional hyperthermic isolated limb perfusion. *Nucl Med Commun* 32: 853-862, 2011.
60. **Wilting KR, Kampinga GA, van Leeuwen JT, Slart RH and Sprenger HG.** Fever and persisting cough. *Neth J Med* 69: 454-464, 2011.
61. **Wolfensberger SP, Maruyama K, van Berckel BN, Lubberink M, Airaksinen AJ, Boellaard R, Luurtsema G, Reddingius W, Janssens FE, Veltman DJ, Windhorst AD, Leysen JE and Lammertsma AA.** Quantification of the neurokinin 1 receptor ligand [11C]R116301. *Nucl Med Commun* 32: 896-902, 2011.

62. **Woolthuis C, Agool A, Olthof S, Slart RH, Huls G, Smid WM, Schuringa JJ and Vellenga E.** Auto-SCT induces a phenotypic shift from CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and in vivo cycling activity defined by (18)F-FLT PET scanning. *Bone Marrow Transplant* 46: 110-115, 2011.
63. **Wu C, de Jong JR, Gratama van Andel HA, van der Have F, Vastenhouw B, Laverman P, Boerman OC, Dierckx RA and Beekman FJ.** Quantitative multi-pinhole small-animal SPECT: uniform versus non-uniform Chang attenuation correction. *Phys Med Biol* 56: N183-N193, 2011.

WILL APPEAR IN 2012

1. **Antunes IF, Haisma HJ, Elsinga PH, van Waarde A, Willemsen AT, Dierckx RA and de Vries EF.** In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-beta-d-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging beta-Glucuronidase Activity in a Tumor/Inflammation Rodent Model. *Mol Imaging* 2011. (epub, in press)
2. **Dobos N, de Vries EF, Kema IP, Patas K, Prins M, Nijholt IM, Dierckx RA, Korf J, den Boer JA, Luiten PG and Eisel UL.** The Role of Indoleamine 2,3-Dioxygenase in a Mouse Model of Neuroinflammation-Induced Depression. *J Alzheimers Dis* 28:905-915,2012.
3. **Duiker E, Dijkers ECF, Lambers Heerspink H, de Jong S, van der Zee AGJ, Jager PL, Kosterink JGW, de Vries EGE and Lub-de Hooge M.** Development of radioiodinated rhTRAIL and a radiolabelled agonistic TRAIL receptor antibody for clinical imaging studies. *Br J Pharmacol* 2011. . (epub, in press)
4. **Fiebrich HB, van Asselt SJ, Brouwers AH, van Dullemen HM, Pijl ME, Elsinga PH, Links TP and de Vries EG.** Tailored imaging of islet cell tumors of the pancreas amidst increasing options. *Crit Rev Oncol Hematol* 2011. . (epub, in press)
5. **Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG and Schroder CP.** Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer. *J Clin Oncol* 30:e74-e75,2012
6. **Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJ, Hospers GA and Hoekstra HJ .** Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. *Ann Surg Oncol* 19:620-626,2012

7. **Malviya G, Anzola KL, Podesta E, Lagana B, Del MC, Dierckx RA, Scopinaro F and Signore A.** (99m)Tc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients. *Mol Imaging Biol* 2011. . (epub, in press)
8. **Plattel WJ, van den Berg A, Visser L, van der Graaf AM, Pruijm J, Vos H, Hepkema BG, Diepstra A and van Imhoff GW.** Plasma thymus and activation-regulated chemokine as an earlyresponse marker in classical Hodgkin lymphoma. *Haematologica* 97:410-415,2012
9. **Schreurs LM, Janssens AC, Groen H, Fockens P, van Dullemen HM, Berge Henegouwen MI, Sloof GW, Pruijm J, van Lanschot JJ, Steyerberg EW and Plukker JT.** Value of EUS in Determining Curative Resectability in Reference to CT and FDG-PET: The Optimal Sequence in Preoperative Staging of Esophageal Cancer? *Ann Surg Oncol* 2011. . (epub, in press)
10. **Stojanov K, de Vries EF, Hoekstra D, van Waarde A, Dierckx RA and Zuhorn IS.** [(18)F]FDG Labeling of Neural Stem Cells for In Vivo Cell Tracking with Positron Emission Tomography: Inhibition of Tracer Release by Phloretin. *Mol Imaging* 2011. . (epub, in press)
11. **van Leeuwen AC, Huddleston Slater JJ, Gielkens PF, de J, Jr., Grijpma DW and Bos RR.** Guided bone regeneration in rat mandibular defects using resorbable poly(trimethylene carbonate) barrier membranes. *Acta Biomater* 8:1422-1429,2012.